RRPV BoNT-NMJ

The Administration for Strategic Preparedness and Response (ASPR) issued this sources sought notice, identified as solicitation number SSN-BARDA-04202026, to conduct market research regarding neuromuscular junction (NMJ) micro-physiological systems. The Biomedical Advanced Research and Development Authority (BARDA) seeks to identify human-relevant in vitro platforms capable of measuring Botulinum neurotoxin (BoNT) potency and evaluating the efficacy of medical countermeasures. This initiative aims to determine if NMJ-based platforms can support the development of validated assays that reduce or replace current reliance on mouse-based bioassays, such as the Mouse Potency Assay and Mouse Neutralization Assay.

The scope focuses on systems that provide mechanistic insight into how botulinum neurotoxins inhibit acetylcholine release through the cleavage of SNARE proteins. BARDA is specifically interested in platforms demonstrating the recovery of neuronal signaling, making them suitable for evaluating medical countermeasures. This requirement is classified under NAICS 541714 for Research and Development in Biotechnology (except Nanobiotechnology) and PSC 6505 for Drugs and Biologicals.

The primary place of performance is Washington, DC, and responses to this notice are due by May 11, 2026. Kathy Garee is the designated point of contact for this market research effort. One attachment, titled RRPV_RFI_BoNT-NMJ RFI.pdf, was included with the notice published on April 20, 2026.